Krystal Biotech is trading 4.1% lower at $316.55 as biotech and broader-market weakness is the likeliest explanation, though no direct cause for the stock’s decline is established. - XBI is down 2.06%, and major indexes are also lower. - No fresh company-specific catalyst for the October 16 decline surfaced. Positive KB113 Gorlin syndrome data announced October 15 is prior news, not a clear explanation.